Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2016; 8(9): 682-687
Published online Sep 15, 2016. doi: 10.4251/wjgo.v8.i9.682
Pancreatic cancer: New hopes after first line treatment
Francesca Aroldi, Paola Bertocchi, Giordano Savelli, Edoardo Rosso, Alberto Zaniboni
Francesca Aroldi, Paola Bertocchi, Alberto Zaniboni, Department of Medical Oncology, Poliambulanza Foundation, 25124 Brescia, Italy
Giordano Savelli, Department of Nuclear Medicine, Poliambulanza Foundation, 25124 Brescia, Italy
Edoardo Rosso, Department of General Surgery, Poliambulanza Foundation, 25124 Brescia, Italy
Author contributions: Aroldi F, Bertocchi P, Savelli G and Rosso E contributed equally to this work and wrote the paper; while Zaniboni A made critical revisions related to important intellectual content of the manuscript and approved the final version of the article.
Conflict-of-interest statement: The authors declare that they do not have any conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Alberto Zaniboni, MD, Department of Medical Oncology, Poliambulanza Foundation, via Bissolati 57, 25124 Brescia, Italy.
Telephone: +39-30-3515553 Fax: +39-30-3518270
Received: March 26, 2016
Peer-review started: March 27, 2016
First decision: May 17, 2016
Revised: June 7, 2016
Accepted: July 14, 2016
Article in press: July 18, 2016
Published online: September 15, 2016

Pancreatic cancer is the fourth leading cause of cancer-related death worldwide. Extensive research has yielded advances in first-line treatment strategies, but there is no standardized second-line therapy. In this review, we examine the literature trying to establish a possible therapeutic algorithm.

Keywords: Nab-paclitaxel, Nal-iri, Pancreatic cancer, Second line, Algorithm

Core tip: Pancreatic cancer is an emerging disease. In this review a possible therapeutic algorithm for second line treatment is hypothesized.